General Information of Drug (ID: DM5JJ83)

Drug Name
Varespladib Drug Info
Synonyms
Varespladib; 172732-68-2; LY315920; Varespladib (LY315920); LY-315920; S-5920; VAREPLADIB; 2Q3P98DATH; ({3-[amino(oxo)acetyl]-1-benzyl-2-ethyl-1H-indol-4-yl}oxy)acetic acid; 2-(1-benzyl-2-ethyl-3-oxamoylindol-4-yl)oxyacetic acid; CHEMBL148674; S 5920; 2-((3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid; 2-(3-(2-amino-2-oxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yloxy)acetic acid; SMR004701444; Varespladib [INN]; Varespladib [USAN]; Varespladib [USAN:INN]; UNII-2Q3P98DATH; varespladibum; ((3-(AMINO(OXO)ACETYL)-1-BENZYL-2-ETHYL-1H-INDOL-4-YL)OXY)ACETIC ACID; VRD; VARESPLADIB [MI]; Varespladib (USAN/INN); SCHEMBL26726; VARESPLADIB [WHO-DD]; MLS006010414; MLS006010980; varespladib methyl (A-002); varespladib sodium (A-001); LY 315920 (Varespladib); GTPL9657; DTXSID50169378; EX-A153; CHEBI:189668; BCPP000175; HMS3654E04; HMS3744O03; AMY19698; BCP01854; BDBM50055366; MFCD00944812; s1110; ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)acetate; AKOS015842901; compound 6m [PMID: 8978844]; BCP9000883; CCG-268404; DB11909; EX-8676; SB16690; NCGC00346491-01; NCGC00346491-02; NCGC00346491-08; NCGC00346491-12; AC-32931; AS-16956; HY-13402; A-001; FT-0659937; SW219559-1; A25228; D08107; EN300-144829; J-010846; Q7915613; BRD-K09711437-001-01-9; Z1721255146; (3-Aminooxalyl-1-benzyl-2-ethyl-1H-indol-4-yloxy)-acetic acid; 2-[2-ethyl-3-oxamoyl-1-(phenylmethyl)indol-4-yl]oxyethanoic acid; ((3-(Aminooxoacetyl)-1-benzyl-2-ethyl-1H-indol-4-yl)oxy)acetic acid; (3-Aminooxalyl-1-benzyl-2-ethyl-2,3-dihydro-1H-indol-4-yloxy)-acetic acid; 2-{[1-benzyl-3-(carbamoylcarbonyl)-2-ethyl-1H-indol-4-yl]oxy}acetic acid; ACETIC ACID, ((3-(AMINOOXOACETYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL)OXY)-; Acetic acid, ((3-(aminooxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)-,; LY 315920; Varespladib; 2-[[3-(2-Amino-2-oxoacetyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic aci
Indication
Disease Entry ICD 11 Status REF
Snakebite N.A. Phase 2 [1]
Cross-matching ID
PubChem CID
155815
TTD Drug ID
DM5JJ83

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phospholipase A2 (PLA2G1B) TT9V5JH PA21B_HUMAN Not Available [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Phospholipase A2 (PLA2G1B) DTT PLA2G1B 5.385 3.733 4.178 5.278
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Snakebite
ICD Disease Classification N.A.
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Phospholipase A2 (PLA2G1B) DTT PLA2G1B 2.65E-01 -0.08 -0.21
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05717062) Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Intravenous Varespladib Followed by Oral Varespladib in Addition to Standard of Care in Subjects Bitten by Venomous Snakes. U.S.National Institutes of Health.
2 Varespladib in the Treatment of Snakebite Envenoming: Development History and Preclinical Evidence Supporting Advancement to Clinical Trials in Patients Bitten by Venomous Snakes. Toxins (Basel). 2022 Nov 11;14(11):783.